Opioid crisis cost US government nearly $38 billion in lost taxes

pharmafile | April 11, 2019 | News story | Medical Communications, Research and Development US, government, opioid crisis, opioids, public health, tax revenue 

The opioid epidemic may have cost US state and federal governments as much as $37.8 billion in lost tax revenue, according to researchers from Pennsylvania State University.

Opioid related loss of employment cost the government billions in lost tax revenue between the years 2000 and 2016, the research says.

The state of Pennsylvania was found to be one of the biggest losers, having lost around $638.2 million in income and sales taxes, the study published in the journal Medical Care says.

While previous studies have looked at the costs associated with treatment for addiction and other associated medical care, Joel Segel, assistant professor of Health Policy and Administration, sought to look at the opioid epidemic in terms of tax revenues.

Segel commented: “This is a cost that was maybe not thought about as explicitly before, and a cost that governments could potentially try to recoup. Instead of focusing on the cost of treating people with opioid use disorder, you could think about it in terms of a potential benefit to getting people healthy, back on their feet, and back in the workforce”

The Penn State researchers found 1.6 million fewer people participated in the workforce between 2000 and 2016. This led to a loss of $11.8 billion to state governments and a loss of $26 billion to federal governments in tax revenue.  

“We wanted to take a systematic approach to how we could think about some of the tax revenue that is lost if someone is unable to work due to opioid use,” Segel said. “This could be an important consideration for either state or federal budgets.”

The research emphasises the importance of substance abuse treatment programmes. “Not only are treatment programs beneficial to the individual and to society, but if you’re thinking about the total cost of these treatment programs, future earnings from tax revenue could help offset a piece of that,” Segel said.

Louis Goss

Related Content

FDA approves a second OTC naloxone nasal spray

The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg …

FDA approves prescription nasal spray for opioid overdose treatment

The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the …

Expansion for first FDA-approved video game for ADHD treatment

Akili Interactive has announced the expansion of its prescription video game treatment, EndeavorRx, with the …

Latest content